Campaign Story

BioInk Labs was founded to address one of healthcare’s greatest challenges: organ shortages and expensive clinical trials. Every year, thousands of patients in India die waiting for transplants, while pharmaceutical companies spend millions testing drugs on outdated models. BioInk Labs is changing that with its 3D bioprinting platform, which uses bio-inks made from stem cells to print functional tissue models and simplified organ structures.

The technology allows doctors to simulate surgeries, test drug effects, and study disease progression on realistic tissue models—cutting costs and improving patient safety. In pilot collaborations with two Mumbai hospitals, BioInk successfully printed liver tissue samples that mimicked real patient responses. Doctors praised its potential for reducing reliance on animal testing, while pharma companies saw massive cost-saving opportunities.

But despite its promise, BioInk is financially collapsing. High R&D costs, regulatory hurdles, and lack of consistent backing have drained its resources. The team of scientists is shrinking, lab equipment is overdue for payments, and partnerships risk falling apart. Without urgent capital, the startup’s groundbreaking research could be lost.

India’s biotech sector is expanding, and BioInk could put the country at the forefront of bioprinting innovation. But without immediate support, the vision of affordable, life-saving organ and tissue technology will remain unfinished.